Healthcare / Diagnostics & ResearchNasdaqGM
$5.35
+0.37 (+7.43%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-14.3M · quality 51.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
26/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$129M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-114.3%
↓Gross Margin
58.3%
↑Debt/Equity
1.47
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2018–2025 · 7 años de histórico normalizado
Revenue CAGR
+10.8%
FCF CAGR
—
FCF margin
-21.4%
FCF / Net income
0.72x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $66.6M · net income $-20.0M · FCF $-14.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | $66.6M | $66.6M | $55.6M | $52.5M | $45.6M | $48.3M | $42.0M | $40.4M | $32.4M |
| Net Income | $-20.0M | $-20.0M | $-15.1M | $-23.7M | $-47.4M | $-26.9M | $-16.7M | $-12.0M | $-8.0M |
| EBITDA | $-13.5M | $-13.5M | $-11.1M | $-19.2M | $-43.7M | $-23.2M | $-14.7M | $-8.7M | $-4.3M |
| EPS | — | — | -0.83 | -1.34 | -2.77 | -1.68 | -1.32 | — | — |
| Gross Margin | 58.3% | 58.3% | 59.5% | 56.1% | 46.9% | — | — | — | — |
| Operating Margin | -21.1% | -21.1% | -24.5% | -43.5% | -89.0% | -49.8% | -36.2% | -23.0% | -15.0% |
| Net Margin | -30.0% | -30.0% | -27.2% | -45.1% | -104.0% | -55.6% | -39.8% | -29.8% | -24.7% |
| Balance Sheet | |||||||||
| Debt/Equity | 1.47 | 1.47 | 2.43 | 1.02 | 0.83 | 0.32 | 0.64 | 0.46 | -0.22 |
| Current Ratio | 3.47 | 3.47 | — | — | — | — | — | — | — |
| Cash Flow | |||||||||
| Free Cash Flow | $-14.3M | $-14.3M | $-13.8M | $-15.3M | $-36.5M | $-22.6M | $-14.5M | $-10.1M | $-9.5M |
| Returns | |||||||||
| ROE | -114.3% | -114.3% | -158.4% | -104.4% | -111.6% | -31.6% | -39.9% | -21.6% | 7.2% |
| Valuation | |||||||||
| P/B | 7.02 | 7.02 | 6.83 | 1.49 | 1.00 | — | — | — | — |
| Growth & Yield | |||||||||
| Revenue Growth | 19.7% | 19.7% | 5.9% | 15.3% | — | 15.1% | 3.9% | 24.5% | — |
| EPS Growth | — | — | 38.1% | 51.6% | — | -27.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-23.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.83 → n/d
Residual
-23.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.